Engineering synthetic vaccines using cues from natural immunity.
暂无分享,去创建一个
[1] Dan Peer,et al. Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.
[2] R. Langer,et al. A single-step immunization by sustained antigen release. , 1979, Journal of immunological methods.
[3] K. Leong,et al. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. , 2012, Nature materials.
[4] P. Cresswell,et al. Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles , 2006, Immunology.
[5] D. Irvine,et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.
[6] I. M. Belyakov,et al. Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection , 2012, Nature Medicine.
[7] John Steel,et al. Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.
[8] D. Irvine,et al. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles , 2011, Proceedings of the National Academy of Sciences.
[9] T. Kündig,et al. Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.
[10] T. Wisniewski,et al. Immunomodulation for prion and prion-related diseases , 2010, Expert review of vaccines.
[11] L. Zender,et al. T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.
[12] P. Kozlowski,et al. Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.
[13] C. Coban,et al. DNA released from dying host cells mediates aluminum adjuvant activity , 2011, Nature Medicine.
[14] C. Klebanoff,et al. Therapeutic cancer vaccines: are we there yet? , 2011, Immunological reviews.
[15] Samuel K. Lai,et al. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses , 2009, Proceedings of the National Academy of Sciences.
[16] J. Mcghee,et al. Novel vaccine development strategies for inducing mucosal immunity , 2012, Expert review of vaccines.
[17] Justin Hanes,et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.
[18] Pau Serra,et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. , 2010, Immunity.
[19] J. Hubbell,et al. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. , 2012, Biomaterials.
[20] J. Hubbell,et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination , 2011, Proceedings of the National Academy of Sciences.
[21] R. Locksley,et al. The regulation of immunity to Leishmania major. , 1995, Annual review of immunology.
[22] David J Mooney,et al. In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.
[23] Roger Le Grand,et al. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[24] Francesco Stellacci,et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.
[25] Scott N. Mueller,et al. High antigen levels are the cause of T cell exhaustion during chronic viral infection , 2009, Proceedings of the National Academy of Sciences.
[26] Hans P. Merkle,et al. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres : importance of polymer degradation and antigen release for immune response , 1996 .
[27] Yen Cu,et al. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[28] J. Villadangos,et al. The cell biology of cross‐presentation and the role of dendritic cell subsets , 2008, Immunology and cell biology.
[29] N. Haigwood,et al. The Use of Nonhuman Primate Models in HIV Vaccine Development , 2008, PLoS medicine.
[30] J. Hubbell,et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. , 2011, Vaccine.
[31] L. Harrison. Vaccination against self to prevent autoimmune disease: the type 1 diabetes model , 2008, Immunology and cell biology.
[32] R. Zinkernagel,et al. The influence of antigen organization on B cell responsiveness. , 1993, Science.
[33] Karan Sharma,et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. , 2008, Immunity.
[34] C. Hung,et al. HPV and Therapeutic Vaccines: Where are We in 2010? , 2010 .
[35] J. Remon,et al. Facile two-step synthesis of porous antigen-loaded degradable polyelectrolyte microspheres. , 2010, Angewandte Chemie.
[36] S. Dow,et al. Efficient Immunization and Cross-Priming by Vaccine Adjuvants Containing TLR3 or TLR9 Agonists Complexed to Cationic Liposomes1 , 2006, The Journal of Immunology.
[37] Daniel G. Anderson,et al. pH-Triggered Microparticles for Peptide Vaccination , 2004, The Journal of Immunology.
[38] R. Valenta,et al. Vaccines for allergy , 2012, Current opinion in immunology.
[39] F. Caruso,et al. Enzyme encapsulation in layer-by-layer engineered polymer multilayer capsules. , 2000 .
[40] Jangwook P. Jung,et al. A self-assembling peptide acting as an immune adjuvant , 2009, Proceedings of the National Academy of Sciences.
[41] Ronald N Germain,et al. Vaccines and the future of human immunology. , 2010, Immunity.
[42] F. Caruso,et al. Binding, Internalization, and Antigen Presentation of Vaccine‐Loaded Nanoengineered Capsules in Blood , 2008 .
[43] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[44] C. Foged,et al. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[45] E. Lavelle,et al. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants , 2010, European journal of immunology.
[46] Polly Matzinger,et al. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.
[47] R. Steinman,et al. Taking dendritic cells into medicine , 2007, Nature.
[48] Melody A Swartz,et al. Autologous morphogen gradients by subtle interstitial flow and matrix interactions. , 2006, Biophysical journal.
[49] Benjamin C. Tang,et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier , 2009, Proceedings of the National Academy of Sciences.
[50] Michael Sela,et al. Therapeutic vaccines in autoimmunity , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[51] M. Bevan,et al. Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8− Dendritic Cells In Vivo , 2002, The Journal of experimental medicine.
[52] Demetri Psaltis,et al. Precision intracellular delivery based on optofluidic polymersome rupture. , 2012, ACS nano.
[53] R. Medzhitov,et al. Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.
[54] Mary E Napier,et al. PRINT: a novel platform toward shape and size specific nanoparticle theranostics. , 2011, Accounts of chemical research.
[55] James E. Evans,et al. Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.
[56] N. Van Rooijen,et al. Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses , 2012, Science Translational Medicine.
[57] Wah Chiu,et al. Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.
[58] J. Ulmer,et al. Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles , 2003, Journal of Virology.
[59] Shuzhao Li,et al. Systems vaccinology: learning to compute the behavior of vaccine induced immunity , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[60] C. Liu,et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.
[61] Francisco J. Quintana,et al. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis , 2012, Proceedings of the National Academy of Sciences.
[62] R. Germain,et al. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis , 1995, The Journal of experimental medicine.
[63] Bali Pulendran,et al. The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). , 2009, Biomaterials.
[64] J. DeSimone,et al. Development of a nanoparticle-based influenza vaccine using the PRINT technology. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[65] Jie Li,et al. Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.
[66] J. Hubbell,et al. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. , 2010, Vaccine.
[67] B. Walker,et al. Immunology and the elusive AIDS vaccine , 2010, Nature.
[68] Jean Paul Remon,et al. Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. , 2012, ACS nano.
[69] Benjamin C. Tang,et al. Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus , 2012, Science Translational Medicine.
[70] J. Hubbell,et al. Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice , 2013, PloS one.
[71] Ryan F. Donnelly,et al. Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses , 2013, ACS nano.
[72] W. J. Meek,et al. THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. , 1938, Science.
[73] M. Willart,et al. Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. , 2012, Angewandte Chemie.
[74] R. Valenta,et al. From allergen genes to allergy vaccines. , 2010, Annual review of immunology.
[75] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[76] J. Stockman,et al. Dissolving polymer microneedle patches for influenza vaccination , 2012 .
[77] S. Amigorena,et al. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ–resident dendritic cells , 2013, The Journal of experimental medicine.
[78] Darrell J Irvine,et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. , 2007, Nano letters.
[79] M. Jenkins,et al. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. , 2007, Immunity.
[80] Aaron J. Martin,et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis , 2012, Nature Biotechnology.
[81] Jun Jiao,et al. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response , 2011, Nature nanotechnology.
[82] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[83] L. Holm,et al. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[84] A. Gettie,et al. Protection against vaginal SIV transmission with microencapsulated vaccine. , 1993, Science.
[85] K. Rock,et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.
[86] M. Kovacsovics-Bankowski,et al. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules , 1995, Science.
[87] Naveen Palath,et al. Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses. , 2013, Vaccine.
[88] Richard A Flavell,et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. , 2009, Vaccine.
[89] Michael S Roberts,et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. , 2010, Small.
[90] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[91] R. Gupta,et al. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. , 1996, Vaccine.
[92] Jamal S. Lewis,et al. Microparticle surface modifications targeting dendritic cells for non-activating applications. , 2012, Biomaterials.
[93] E. Wherry,et al. Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.
[94] H. Lindén,et al. The European Federation for Pharmaceutical Sciences , 2003 .
[95] I. M. Belyakov,et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. , 2010, The Journal of clinical investigation.
[96] Thomas Krucker,et al. Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.
[97] E. Dolgin. The inverse of immunity , 2010, Nature Medicine.
[98] Li Tang,et al. Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. , 2012, ACS nano.
[99] M. Galinski,et al. The relevance of non-human primate and rodent malaria models for humans , 2011, Malaria Journal.
[100] L. Old,et al. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient , 2008, Cancer Immunology, Immunotherapy.
[101] Christopher B Wilson,et al. A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design. , 2010, Immunity.
[102] S. Schwendeman,et al. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) , 2000, Nature Biotechnology.
[103] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[104] Manmohan J. Singh,et al. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[105] J. Hubbell,et al. PEG-b-PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA: tumor immunotoxicity in B16F10 melanoma. , 2011, Biomaterials.
[106] K. Wittrup,et al. Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency1 , 2008, The Journal of Immunology.
[107] M. Swartz,et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. , 2012, Cell reports.
[108] Ping Zhang,et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity , 2011, Nature Medicine.
[109] C. Figdor,et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. , 2011, Blood.
[110] H. Kiyono,et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. , 2010, Nature materials.
[111] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[112] Jean M. J. Fréchet,et al. A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[113] Ashutosh Kumar Singh,et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[114] J. Ravetch,et al. Antibody‐mediated modulation of immune responses , 2010, Immunological reviews.
[115] P. Marrack,et al. Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.
[116] Paula T Hammond,et al. Polymer multilayer tattooing for enhanced DNA vaccination. , 2013, Nature materials.
[117] J. Hubbell,et al. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. , 2011, Biomaterials.
[118] Jeffrey A Hubbell,et al. Engineering Approaches to Immunotherapy , 2012, Science Translational Medicine.
[119] J. Tschopp,et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.
[120] Carl A. Batt,et al. Single-Walled Carbon Nanotubes Deliver Peptide Antigen into Dendritic Cells and Enhance IgG Responses to Tumor-Associated Antigens , 2011, ACS nano.
[121] H. M. Nielsen,et al. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[122] S. Broderick,et al. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. , 2011, Biomaterials.
[123] V. Appay,et al. CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.
[124] Michael S. Goldberg,et al. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery , 2012, Proceedings of the National Academy of Sciences.
[125] A. Rudensky,et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. , 2003, Immunity.
[126] David J. Mooney,et al. Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.
[127] D. Irvine,et al. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[128] S. Plotkin,et al. Vaccines: past, present and future , 2005, Nature Medicine.
[129] James Mitchell Crow,et al. HPV: The global burden , 2012, Nature.
[130] A. Aderem,et al. A 2020 vision for vaccines against HIV, tuberculosis and malaria , 2011, Nature.
[131] Shizuo Akira,et al. The roles of TLRs, RLRs and NLRs in pathogen recognition. , 2009, International immunology.
[132] D. Irvine,et al. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. , 2011, Molecular pharmaceutics.